Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE–SPE–HPLC

Yamamoto, Eiichi; Hyôdô, Kenji; Ohnishi, Naozumi; Suzuki, Takuya; Ishiguro, Hiroshi; Kikuchi, Hiroshi; Asakawa, Naoki

doi:10.1016/j.jchromb.2011.10.004

Cited by 42 publications

(17 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These separation methods have a potential risk of sample deterioration: adsorption to ultrafiltration devices, high sample dilution during gel chromatography, and drug release from the liposomes during reversed phase SPE. 22) To circumvent these difficulties, we developed simple online SPE of released and encapsulated drugs in the plasma using a column-switching HPLc system 23) …”

Section: Development Of Analytical Methods To Ensure the Quality Of Dmentioning

confidence: 99%

“…24,28) This direct plasma injection approach using the proposed SPE-SPE-HPLc system made it possible to simultaneously measure the encapsulated and released drugs in plasma. 23) The methodology enabled us to determine the in vivo properties of liposomes and contribute to the efficient creation of liposomal drug product.…”

Section: Fig 2 Abc Phenomenon Of Peg-modified Liposomesmentioning

confidence: 99%

See 1 more Smart Citation

Development of Liposomal Anticancer Drugs

Hyôdô

Yamamoto

Suzuki

et al. 2013

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Liposomes are drug delivery systems that can alter the pharmacokinetic properties of compounds. The adverse effects of anticancer agents are a limiting factor for cancer chemotherapy, therefore, liposomal formulations have the potential to improve the therapeutic efficacy of anticancer agents by enhancing their accumulation in tumors and reducing non-selective distribution to normal tissues, which is known as the enhanced permeability and retention effect. To develop a liposomal anticancer agent as a drug product, its formulation must be designed to ensure its quality until it is administered to patients and to exert maximum potency in clinical use rather than in animal experiments. The chemical stability and physicochemical stability of the ingredients are key factors in the design of liposomal formulations. Drug release rates are critical factors in the therapeutic efficacy of liposomal drug products because the encapsulated drug has no pharmacological activity, and only released drug can exert antitumor/toxic activities. Liposomes should maintain the drug in a stable state in the circulation and then promptly release it after accumulation in the target tissue in order to achieve a sufficient drug concentration. To understand the profile of the formulation and to guarantee the quality of drug product, a reliable analytical method that can determine the released and encapsulated drugs in biological fluids is required. Simple online solid phase extractions of the released and encapsulated drugs using a column-switching HPLC system meet the requirements and this system enables accurate in vitro release testing and in vivo pharmacokinetic evaluation. This review introduces the process of liposomal drug product development from various viewpoints.

show abstract

Section: Development Of Analytical Methods To Ensure the Quality Of Dmentioning

confidence: 99%

Section: Fig 2 Abc Phenomenon Of Peg-modified Liposomesmentioning

confidence: 99%

Development of Liposomal Anticancer Drugs

Hyôdô

Yamamoto

Suzuki

et al. 2013

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interactions between the solid phase sorbent and NBCD can be minimized through changes in solid phase chemistries and mobile phase, and passivation of the solid phase (e.g. by albumin treatment) (Bellott et al 2001;Thies et al 1990;Yamamoto et al 2011). Clearly, it is important to use a separation method that is accurate and preserves the NBCD release characteristics.…”

Section: Solid Phase Extractionmentioning

confidence: 99%

Non-Biological Complex Drugs

Crommelin¹,

Vlieger²

2015

AAPS Advances in the Pharmaceutical Sciences Series

View full text Add to dashboard Cite

“…To overcome these defects, Yamamoto et al developed a column switching HPLC system to analyze the amount of drug within nanoparticles without manual pretreatment [19]. The system separated nanoparticles and free drug first by a restricted access solid-phase extraction column; release of the encapsulated drug from the nanomedicine was performed by HPLC.…”

Section: Introductionmentioning

confidence: 99%

Rapid evaluation of the quantity of drugs encapsulated within nanoparticles by high-performance liquid chromatography in a monolithic silica column

2015

View full text Add to dashboard Cite

Drug-containing nanoparticles, the foundation of nanomedicine, provide promise for the safe and effective delivery of drugs to their targets. In this study, we developed a simple method to determine the relative quantities of nanoparticle-encapsulated drugs by HPLC using a commercially available monolithic silica column. Amphotericin B- and irinotecan-containing nanoparticles produced nearly simultaneous elution peaks (~7 min), suggesting that elution was largely driven by hydrodynamic effects and was relatively unaffected by differences in the encapsulated drug. A good correlation was observed between the intensity of the nanoparticle peak and the relative quantity of encapsulated drug. We used our method to characterize the effects of drug quantity and nanoparticle size on drug encapsulation rates within the nanoparticles. Encapsulation increased with increasing quantities of the drug in the preparation solution. This effect was greater for irinotecan than for amphotericin B. Although absolute encapsulation also increased with increasing nanoparticle size, encapsulation efficiency decreased. Thus, the monolith column is suitable for evaluating nanomedicine quality and may be used to evaluate many kinds of nanomaterials. Graphical Abstract Evaluation method of quantity of drug encapsulated within nanoparticles was developed. The method can be applicable for a rapid quality assurance of nanomedicine.

show abstract

Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE–SPE–HPLC

Cited by 42 publications

References 47 publications

Development of Liposomal Anticancer Drugs

Development of Liposomal Anticancer Drugs

Non-Biological Complex Drugs

Rapid evaluation of the quantity of drugs encapsulated within nanoparticles by high-performance liquid chromatography in a monolithic silica column

Contact Info

Product

Resources

About